A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States

Expert Review of Clinical Pharmacology

Volumn 7, Issue 3, 2014, Pages 341-348

  Blieden, Marissa ^a   Paramore, L Clark ^a   Shah, Dhvani ^b   Ben Joseph, Rami ^b  

^a EVIDERA   (United States)

^b PURDUE PHARMA L P   (United States)

Author keywords

Acetaminophen; Epidemiology; Exposure; Liver failure; Opioids; Overdose; Toxicity

Indexed keywords

HYDROCODONE BITARTRATE PLUS PARACETAMOL; OPIATE; PARACETAMOL; ANALGESIC AGENT; NARCOTIC ANALGESIC AGENT;

ACUTE LIVER FAILURE; ANALGESIA; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; DRUG EXPOSURE; DRUG INTOXICATION; DRUG MEGADOSE; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; GASTROINTESTINAL DISEASE; HOSPITALIZATION; HUMAN; LIVER INJURY; LIVER TOXICITY; LONG TERM EXPOSURE; LOW DRUG DOSE; MEDICATION ERROR; MUSCULOSKELETAL DISEASE; PERIPHERAL NEUROPATHY; PRESCRIPTION; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; TOXIC HEPATITIS; UNITED STATES; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG COMBINATION; DRUG POTENTIATION; DRUG-INDUCED LIVER INJURY; EPIDEMIOLOGY; KIDNEY DISEASES; TOXICITY;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG OVERDOSE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; HUMANS; KIDNEY DISEASES; RISK FACTORS; UNITED STATES;

EID: 84898863347     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.904744     Document Type: Review

References (35)

1. Ferguson E, Nelson L. Summary Minutes of the Joint Meeting of the Drug Safety and Risk Management Advisory Committee, Nonprescription Drugs Advisory Committee, and the Anesthetic and Life Support Drugs Advisory Committee of the U.S. Food and Drug Administration to Address the Public Health Problem of Liver Injury Related to the Use of Acetaminophen in Both Over-the-Counter and Prescription Products. Held June 29 and 30, 2009 at Adelphi, MD. Food and Drug Administration, Silver Spring, MD (2009). Available from: www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeeting Materials/Drugs/DrugSafetyandRisk ManagementAdvisoryCommittee/ UCM179888.pdf [Last accessed on October 2013]
2. Acetaminophen overdose. Medline Plus, a Service of the U.S. National Library of Medicine, National Institutes of Health, Bethesda, MD (2013). Available from: www. nlm.nih.gov/medlineplus/ency/article/002598. htm [Last accessed on October 2013]
3. Mitka M. FDA asks physicians to stop prescribing high-dose acetaminophen products. JAMA 2014;311(6):563
4. FDA FDA. Drug. Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. U.S. Food and Drug Administration, Silver Spring, MD (2011). Available from: www.fda.gov/drugs/ drugsafety/ucm239821.htm [Last accessed on October 2013]
5. FDA FDA recommends health care professionals discontinue prescribing and dispensing prescription combination drug products with more than 325 mg of acetaminophen to protect consumers. U.S. Food and Drug Administration, Silver Spring, MD (2014). Available from: www. fda.gov/Drugs/DrugSafety/ucm381644 [Last accessed on 4 March 2014]
6. American Liver Foundation. The American Liver Foundation Issues Warning on Dangers of Excess Acetaminophen. American Liver Foundation, New York (2006). Available from: www. liverfoundation.org/downloads/ alf-download-39.pdf [Last accessed on October 2013]
7. AGS panel on pharmacological management of persistent pain in older persons. Pharmacological Management of Persistent Pain in Older Persons. American Geriatrics Society, New York (2009). Available from: www.americangeriatrics.org/files/documents/ 2009-Guideline.pdf [Last accessed on October 2013]
8. CMS Announces Medicare Part D Overutilization Monitoring System (OMS) for Controlled Substances. Academy of Managed Care Pharmacy, Alexandria, VA (2013). Available from: www.amcp.org/ uploadedFiles/Production-Menu/ Policy-Issues-and-Advocacy/Letters, -Statements-and-Analysis-docs/2013/ CMS-OMS-July2013-Letterhead-Final.pdf [Last accessed on October 2013]
9. Lavonas EJ, Fries JF, Furst DE, et al. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf 2012;11(1):33-44
10. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008;300(24):2867-78
11. Albertson TE, Walker VM Jr, Stebbins MR, et al. A population study of the frequency of high-dose acetaminophen prescribing and dispensing. Ann Pharmacother 2010; 44(7-8):1191-5
12. IMS Institute for Healthcare Informatics. The Use of Medicines in the United States: review of 2011. IMS Institute for Healthcare Informatics, Parsippany, NJ (2012). Availabe from www. environmentalhealthnews.org/ehs/news/ 2013/ pdf-links/IHII-Medicines-in-U.S-Report- 2011-1.pdf [Last accessed on October 2013]
13. Duh MS, Vekeman F, Korves C, et al. Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/ acetaminophen combination prescription pain medications. Pain Med 2010;11(11): 1718-25
14. Mort JR, Shiyanbola OO, Ndehi LN, et al. Opioid-paracetamol prescription patterns and liver dysfunction: a retrospective cohort study in a population served by a US health benefits organization. Drug Saf 2011; 34(11):1079-88
15. Carey EJ, Vargas HE, Douglas DD, et al. Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci 2008;53(7):1977-82
16. Nguyen GC, Sam J, Thuluvath PJ. Hepatitis C is a predictor of acute liver injury among hospitalizations for acetaminophen overdose in the United States: a nationwide analysis. Hepatology 2008;48(4):1336-41
17. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005;42(6): 1364-72
18. Ahmad SR, Elixhauser A, Sutton JP. Hepatotoxicity in Association with Acetaminophen Poisonings in the U.S. Abstract 588, Abstracts of the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Pharmacoepidemiol Drug Saf 2011;20:S256
19. Budnitz DS, Lovegrove MC, Crosby AE. Emergency department visits for overdoses of acetaminophen-containing products. Am J Prev Med 2011;40(6):585-92
20. Nourjah P, Ahmad SR, Karwoski C, Willy M. Estimates of acetaminophen (Paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf 2006;15(6):398-405
21. Michna E, Duh MS, Korves C, Dahl JL. Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications. Pain Med 2010;11(3):369-78
22. Chang YJ, Nourjah P, Ahmad SR, Willy M. OSE Safety Review: Acetaminophen, hepatotoxicity, overdose and death. February 5, 2007. U.S. Food and Drug Administration, Office of Surveillance and Epidemiology, Silver Spring, MD (2007). Available from: www.fda.gov/downloads/ AdvisoryCommittees/ CommitteesMeeting Materials/Drugs/DrugSafetyandRisk ManagementAdvisoryCommittee/ UCM164898.pdf [Last accessed on October 2013]
23. Bower WA, Johns M, Margolis HS, et al. Population-based surveillance for acute liver failure. Am J Gastroenterol 2007;102(11): 2459-63
24. Kane A, Mitchell SJ, Carroll PR, et al. Characteristics of older and younger patients with suspected paracetamol toxicity. Australas J Ageing 2012;31(3):190-3
25. Blackford MG, Felter T, Gothard MD, Reed MD. Assessment of the clinical use of intravenous and oral N-acetylcysteine in the treatment of acute acetaminophen poisoning in children: a retrospective review. Clin Ther 2011;33(9):1322-30
26. Martello JL, Pummer TL, Krenzelok EP. Cost minimization analysis comparing enteral N-acetylcysteine to intravenous acetylcysteine in the management of acute acetaminophen toxicity. Clin Toxicol (Phila) 2010;48(1):79-83
27. Curhan SG, Eavey R, Shargorodsky J, Curhan GC. Analgesic use and the risk of hearing loss in men. Am J Med 2010; 123(3):231-7
28. Curhan SG, Shargorodsky J, Eavey R, Curhan GC. Analgesic use and the risk of hearing loss in women. Am J Epidemiol 2012;176(6):544-54
29. Ho T, Vrabec JT, Burton AW. Hydrocodone use and sensorineural hearing loss. Pain Physician 2007;10(3):467-72
30. FDA FDA Warns of Rare Acetaminophen Risk. US Food and Drug Administration, SIlver Spring, MD (2013). www.fda.gov/ ForConsumers/ ConsumerUpdates/ ucm363010.htm [Last accessed on October 2013]
31. Garcia Rodriguez LA, Hernandez-Diaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res 2001;3(2):98-101
32. Miceli-Richard C, Le Bars M, Schmidely N, Dougados M. Paracetamol in osteoarthritis of the knee. Ann Rheum Dis 2004;63(8): 923-30
33. Rahme E, Pettitt D, LeLorier J. Determinants and sequelae associated with utilization of acetaminophen versus traditional nonsteroidal antiinflammatory drugs in an elderly population. Arthritis Rheum 2002;46(11):3046-54
34. Towheed TE, Maxwell L, Judd MG, et al. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev 2006(1):CD004257
35. Gore M, Sadosky A, Leslie D, et al. Patterns of therapy switching, augmentation, and discontinuation after initiation of treatment with select medications in patients with osteoarthritis. Clin Ther 2011;33(12): 1914-31